Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants

UCSF Chimera—A visualization system for exploratory research and analysis

Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882

[20] Processing of X-ray diffraction data collected in oscillation mode

Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475

Features and development of Coot

Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915

PHENIX : a comprehensive Python-based system for macromolecular structure solution

Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716

Phaser crystallographic software

McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612

NMRPipe: A multidimensional spectral processing system based on UNIX pipes

Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,961

Inference of Macromolecular Assemblies from Crystalline State

Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 10,007

Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein

Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Adams, P. D., Afonine, P. V., Bunkòczi, G., Chen, V. B., Davis, I., Echols, N., Headd, J. J., Hung, L., Kapral, G. J., Grosse‐Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983

Insights on the mutational landscape of the SARS-CoV-2 Omicron variantPreprint

Miller, N. L., Clark, T., Raman, R., & Sasisekharan, R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.06.471499 · Cited by 35

Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera

Vidal, S. J., Collier, A.-R. Y., Yu, J., McMahan, K., Tostanoski, L. H., Ventura, J. D., Aïd, M., Peter, L. E., Jacob-Dolan, C., Anioke, T., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00404-21 · Cited by 34

Chitosan Nanoparticles for Antiviral Drug Delivery: A Novel Route for COVID-19 Treatment

Safer, A.-M., & Leporatti, S. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s332385 · Cited by 34

A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge

Zhou, B., Zhou, R., Tang, B., Chan, J. F., Luo, M., Peng, Q., Yuan, S., Liu, H., Mok, B. W.-Y., Chen, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31259-7 · Cited by 32

Monitoring the spread of the SARS-CoV-2 (Coronaviridae: Coronavirinae: Betacoronavirus; Sarbecovirus) variants in the Moscow region using targeted high-throughput sequencing

Borisova, N. I., Kotov, I. A., Kolesnikov, A. A., Kaptelova, V. V., Speranskaya, A. S., Kondrasheva, L. Y., Tivanova, E. V., Khafizov, K., & Акимкин, В. Г. (2021) · Problems of Virology · doi:10.36233/0507-4088-72 · Cited by 33

The Immune Response to SARS-CoV-2 and Variants of Concern

Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 36

Neutralizing antibodies to SARS‐CoV‐2 variants of concern including Delta and Omicron in subjects receiving mRNA‐1273, BNT162b2, and Ad26.COV2.S vaccines

Zhang, G. F., Meng, W., Chen, L., Ding, L., Feng, J., Pérez, J., Ali, A., Sun, S., Liu, Z., Huang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28032 · Cited by 36

Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques

He, W., Yuan, M., Callaghan, S., Musharrafieh, R. G., Song, G., Silva, M., Beutler, N., Lee, W.-H., Yong, P., Torres, J. L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl9605 · Cited by 32

Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2

Zhou, X., Ma, F., Xie, J., Yuan, M., Li, Y., Shaabani, N., Zhao, F., Huang, D., Wu, N. C., Lee, C.-C. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109109 · Cited by 31

Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations

Cocherie, T., Zafilaza, K., Leducq, V., Marot, S., Cálvez, V., Marcelin, A., & Todesco, È. (2022) · Microorganisms · doi:10.3390/microorganisms11010030 · Cited by 33

Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting

Hauser, B. M., Sangesland, M., Denis, K. S., Lam, E. C., Case, J. B., Windsor, I. W., Feldman, J. E., Caradonna, T. M., Kannegieter, T., Diamond, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110561 · Cited by 38

Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2

Yuan, M., Wang, Y., Lv, H., Tan, T. J. C., Wilson, I. A., & Wu, N. C. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111650 · Cited by 27

Breakthrough infection elicits hypermutated IGHV3-53/3-66 public antibodies with broad and potent neutralizing activity against SARS-CoV-2 variants including the emerging EG.5 lineages

Li, L., Chen, X., Wang, Z., Li, Y., Wang, C., Jiang, L., & Zuo, T. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011856 · Cited by 30

Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies

Sheward, D. J., Pushparaj, P., Das, H., Greaney, A. J., Kim, C., Kim, S., Hanke, L., Hyllner, E., Dyrdak, R., Lee, J., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101577 · Cited by 31

Broadly neutralizing antibodies targeting a conserved silent face of spike RBD resist extreme SARS-CoV-2 antigenic drift

Song, G., Yuan, M., Liu, H., Capozzola, T., Lin, R. N., Torres, J. L., He, W., Musharrafieh, R., Dueker, K., Zhou, P.-P., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115948 · Cited by 30

Structural basis of Omicron neutralization by affinity-matured public antibodiesPreprint

Sheward, D. J., Pushparaj, P., Das, H., Kim, C., Kim, S., Hanke, L., Dyrdak, R., McInerney, G. M., Albert, J., Murrell, B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.03.474825 · Cited by 27

Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron

Liu, H., Kaku, C. I., Song, G., Yuan, M., Andrabi, R., Burton, D. R., Walker, L. M., & Wilson, I. A. (2022) · Communications Biology · doi:10.1038/s42003-022-03700-6 · Cited by 32

Structural Immunology of SARS ‐ CoV ‐2

Yuan, M., & Wilson, I. A. (2024) · Immunological Reviews · doi:10.1111/imr.13431 · Cited by 29

Human monoclonal antibodies targeting A35 protect from death caused by mpox

Fantin, R. F., Yuan, M., Park, S., Bozarth, B., Cohn, H., Ignacio, M. A., Earl, P. L., Civljak, A., Laghlali, G., Zhang, D., et al. (2025) · Cell · doi:10.1016/j.cell.2025.08.004 · Cited by 34

Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models

Sheward, D. J., Mandolesi, M., Urgard, E., Kim, C., Hanke, L., Vidakovics, L. P., Pankow, A. P., Smith, N. L., Dopico, X. C., McInerney, G. M., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100450 · Cited by 28

Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint

Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · medRxiv · doi:10.1101/2021.03.31.21254660 · Cited by 30

Free energy perturbation calculations of mutation effects on SARS-CoV-2 RBD::ACE2 binding affinity

Sergeeva, A. P., Katsamba, P. S., Liao, J., Sampson, J. M., Bahna, F., Mannepalli, S., Morano, N. C., Shapiro, L., Friesner, R. A., & Honig, B. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168187 · Cited by 27

Challenges of vaccination and herd immunity in COVID‐19 and management strategies

She, J., Hou, D., Chen, C., Bi, J., & Song, Y. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13543 · Cited by 28

SARS-CoV-2 Omicron Variants Reduce Antibody Neutralization and Acquire Usage of Mouse ACE2

Wang, R., Zhang, Q., Zhang, R., Aw, Z. Q., Chen, P., Wong, Y. H., Hong, J., Ju, B., Shi, X., Ding, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.854952 · Cited by 29

Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning

Ouyang, W. O., Tan, T. J. C., Lei, R., Song, G., Kieffer, C., Andrabi, R., Matreyek, K. A., & Wu, N. C. (2022) · Science Advances · doi:10.1126/sciadv.add7221 · Cited by 27

Modeling of ACE2 and antibodies bound to SARS-CoV-2 provides insights into infectivity and immune evasion

Lubin, J. H., Markosian, C., Balamurugan, D., Ma, M. T., Chen, C.-H., Liu, D., Pasqualini, R., Arap, W., Burley, S. K., & Khare, S. D. (2023) · JCI Insight · doi:10.1172/jci.insight.168296 · Cited by 26

35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope

Wang, X., Chen, X., Tan, J., Yue, S., Zhou, R., Xu, Y., Lin, Y., Yang, Y., Zhou, Y. W., Deng, K., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.03.035 · Cited by 25

Inhibitory Activity of Saussurea costus Extract against Bacteria, Candida, Herpes, and SARS-CoV-2

Idriss, H., Siddig, B., González-Maldonado, P., El-Khair, H. M., Alakhras, A. I., Abdallah, E. M., Elzupir, A. O., & Sotelo, P. H. (2023) · Plants · doi:10.3390/plants12030460 · Cited by 26

Expression pattern and function of SARS-CoV-2 receptor ACE2

Li, R.-T., & Qin, C. (2021) · Biosafety and Health · doi:10.1016/j.bsheal.2021.08.003 · Cited by 25

Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants

Bayarri‐Olmos, R., Jarlhelt, I., Johnsen, L. B., Hansen, C. B., Helgstrand, C., Bjelke, J. R., Matthiesen, F., Nielsen, S. D., Iversen, K. K., Ostrowski, S. R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.757197 · Cited by 25

Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants

Lin, W., Chen, I.-C., Chen, H., Lee, Y., & Wu, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.795741 · Cited by 26

Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display

Tanaka, S., Olson, C. A., Barnes, C. O., Higashide, W., Gonzalez, M. R., Taft, J. D., Richardson, A., Martín-Fernández, M., Bogunovic, D., Gnanapragasam, P. N. P., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110348 · Cited by 20

Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants

Yu, H., Liu, B., Zhang, Y., Gao, X., Wang, Q., Xiang, H., Peng, X., Xie, C., Wang, Y., Hu, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36761-0 · Cited by 24

Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines

Zhang, Y., Ndzouboukou, J. B., Gan, M., Lin, X., & Fan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.771242 · Cited by 21

A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD

Wang, X., Hu, A., Chen, X., Zhang, Y., Yu, F., Yue, S., Li, A., Zhang, J., Pan, Z., Yang, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00954-8 · Cited by 23

Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab

Magnus, C. L., Hiergeist, A., Schuster, P., Rohrhofer, A., Medenbach, J., Gessner, A., Peterhoff, D., & Schmidt, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.966236 · Cited by 23

Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals

Jaago, M., Rähni, A., Pupina, N., Pihlak, A., Sadam, H., Tuvikene, J., Avarlaid, A., Planken, A., Planken, M., Haring, L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20849-6 · Cited by 23

A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529)

Lu, Y., Li, Q., Fan, H., Liao, C., Zhang, J., Hu, H., Yi, H., Peng, Y., Lu, J., & Chen, Z. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s387160 · Cited by 24

Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development

He, X., He, C., Hong, W., Yang, H. J., & Wei, X. (2023) · Medicinal Research Reviews · doi:10.1002/med.21941 · Cited by 25

The smallest functional antibody fragment: Ultralong CDR H3 antibody knob regions potently neutralize SARS-CoV-2

Huang, R., Jenkins, G. W., Kim, Y., Stanfield, R. L., Singh, A., Martinez‐Yamout, M. A., Kroon, G. J. A., Torres, J. L., Jackson, A. M., Kelley, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303455120 · Cited by 24

Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants

Jeong, B.-S., Cha, J. S., Hwang, I., Kim, U., Adolf‐Bryfogle, J., Coventry, B., Cho, H., Kim, K., & Oh, B. (2022) · mAbs · doi:10.1080/19420862.2021.2021601 · Cited by 21

Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy

Damavandi, A. R., Dowran, R., Sharif, S. A., Kashanchi, F., & Jafari, R. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00729-6 · Cited by 21

An Advanced Healthcare Sensing Platform for Direct Detection of Viral Proteins in Seconds at Femtomolar Concentrations via Aerosol Jet 3D‐Printed Nano and Biomaterials

Ali, M. A., Zhang, F., Hu, C., Yuan, B., Gao, S., & Panat, R. P. (2024) · Advanced Materials Interfaces · doi:10.1002/admi.202400005 · Cited by 21

Evidence of antigenic drift in the fusion machinery core of SARS-CoV-2 spike

Tan, T. J. C., Verma, A. K., Odle, A. E., Lei, R., Meyerholz, D. K., Matreyek, K. A., Perlman, S. M., Wong, L.-Y. R., & Wu, N. C. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2317222121 · Cited by 21

Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages

Li, X., Pan, Y., Yin, Q., Wang, Z., Shan, S., Zhang, L., Yu, J., Qu, Y., Sun, L., Gui, F., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00449-4 · Cited by 20

Antibody cocktail effective against variants of SARS-CoV-2

Liang, K.-H., Chiang, P.-Y., Ko, S.-H., Chou, Y., Lu, R., Lin, H.-T., Wy, C., Lin, Y., Tao, M., Jan, J., et al. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00777-9 · Cited by 19

Structural effects of spike protein D614G mutation in SARS-CoV-2

Dokainish, H., & Sugita, Y. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.11.025 · Cited by 22

Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants

Cui, L., Li, T., Xue, W., Zhang, S., Wang, H., Liu, H., Gu, Y., Xia, N., & Li, S. (2024) · Viruses · doi:10.3390/v16060900 · Cited by 18

Discriminating cross-reactivity in polyclonal IgG1 responses against SARS-CoV-2 variants of concern

van Rijswijck, D. M. H., Bondt, A., Hoek, M., van der Straten, K., Caniels, T. G., Poniman, M., Eggink, D., Reusken, C. B. E. M., de Bree, G. J., Sanders, R. W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33899-1 · Cited by 20

NMR Based SARS-CoV-2 Antibody Screening

Schoenle, M. V., Li, Y., Yuan, M., Clarkson, M. W., Wilson, I. A., Peti, W., & Page, R. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03945 · Cited by 19

Elucidating Design Principles for Engineering Cell‐Derived Vesicles to Inhibit SARS‐CoV‐2 Infection

Gunnels, T. F., Stranford, D. M., Mitrut, R. E., Kamat, N. P., & Leonard, J. N. (2022) · Small · doi:10.1002/smll.202200125 · Cited by 18

FRET-Based haCE2 Receptor Mimic Peptide Conjugated Nanoprobe for Simple Detection of SARS-CoV-2

Kang, B., Lee, Y., Lim, J., Yong, D., Choi, Y. K., Yoon, S. W., Seo, S., Jang, S., Son, S. U., Kang, T., et al. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.136143 · Cited by 20

Stability and expression of SARS-CoV-2 spike-protein mutations

Bæk, K. T., Mehra, R., & Kepp, K. P. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04588-w · Cited by 17

SARS-CoV-2 infection of human lung epithelial cells induces TMPRSS-mediated acute fibrin deposition

Erickson, R. I., Huang, C., Allen, C., Ireland, J., Roth, G., Zou, Z., Lu, J., Lafont, B. A. P., Garza, N. L., Brumbaugh, B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42140-6 · Cited by 19

Identification of a broad sarbecovirus neutralizing antibody targeting a conserved epitope on the receptor-binding domain

Wang, Y., Zhang, Z., Yang, M., Xiong, X., Yan, Q., Cao, L., Wei, P., Zhang, Y., Zhang, L., Lv, K., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2023.113653 · Cited by 16

The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants

Makdasi, E., Zvi, A., Alcalay, R., Noy-Porat, T., Peretz, E., Mechaly, A., Levy, Y., Epstein, E., Chitlaru, T., Tennenhouse, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109679 · Cited by 19

Association of disease severity and death outcome with vaccination status of admitted COVID-19 patients in delta period of SARS-COV-2 in mixed variety of vaccine background

Aslam, J., Hassan, M. R. U., Fatima, Q., Hashmi, H. B., Alshahrani, M. Y., Alkhathami, A. G., & Aneela, I. (2022) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2022.103329 · Cited by 17

Comprehensive structural analysis reveals broad-spectrum neutralizing antibodies against SARS-CoV-2 Omicron variants

Chi, X., Xia, L., Zhang, G., Chi, X., Huang, B., Zhang, Y., Chen, Z., Han, J., Wu, L., Li, Z., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00535-1 · Cited by 16

Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection

Liu, C., Das, R., Dijokaite-Guraliuc, A., Zhou, D., Mentzer, A. J., Supasa, P., Selvaraj, M., Duyvesteyn, H. M. E., Ritter, T. G., Temperton, N. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47393-3 · Cited by 17

Engineering human immune organoids for translational immunology

Suhito, I. R., Sunil, C., & Tay, A. K. P. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.10.010 · Cited by 21

Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants

Yin, R. M., Guest, J. D., Taherzadeh, G., Gowthaman, R., Mittra, I., Quackenbush, J., & Pierce, B. G. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009380 · Cited by 18

Optimization of Anti-SARS-CoV-2 Neutralizing Antibody Therapies: Roadmap to Improve Clinical Effectiveness and Implementation

van der Straten, K., van Gils, M. J., de Taeye, S. W., & de Bree, G. J. (2022) · Frontiers in Medical Technology · doi:10.3389/fmedt.2022.867982 · Cited by 17

Computer Simulations and Network-Based Profiling of Binding and Allosteric Interactions of SARS-CoV-2 Spike Variant Complexes and the Host Receptor: Dissecting the Mechanistic Effects of the Delta and Omicron Mutations

Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084376 · Cited by 18

Reduced B cell antigenicity of Omicron lowers host serologic response

Tubiana, J., Xiang, Y., Fan, L., Wolfson, H. J., Chen, K., Schneidman‐Duhovny, D., & Shi, Y. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111512 · Cited by 18

The (apparent) antibody paradox in COVID-19

Ameratunga, R., Woon, S., Lea, E., Steele, R. H., Lehnert, K., Leung, E. Y., & Brooks, A. E. S. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2044797 · Cited by 16

Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2

Wines, B. D., Kurtovic, L., Trist, H. M., Esparon, S. E., López, E., Chappin, K., Chan, L., Mordant, F. L., Lee, W. S., Gherardin, N. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.889372 · Cited by 15

Pathogen-host adhesion between SARS-CoV-2 spike proteins from different variants and human ACE2 studied at single-molecule and single-cell levels

Zhang, X., Hong, B., Wei, P., Pei, P., Xu, H. C., Chen, L., Tong, Y., Chen, J., Luo, S., Fan, H., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2128887 · Cited by 16

Liposome-based high-throughput and point-of-care assays toward the quick, simple, and sensitive detection of neutralizing antibodies against SARS-CoV-2 in patient sera

Streif, S., Neckermann, P., Spitzenberg, C., Weiß, K. T., Hoecherl, K., Kulikowski, K., Hahner, S., Nölting, C., Einhauser, S., Peterhoff, D., et al. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-04548-3 · Cited by 17

An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological- and endosomal-pH to inhibit virus entry

Lin, X., Guo, L., Lin, S., Chen, Z., Yang, F., Yang, J., Wang, L., Wen, A., Duan, Y., Zhang, X., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2095308 · Cited by 17

Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody: mechanisms for the high infectivity, immune evasion and antibody drug discoveryPreprint

Yin, W., Xu, Y., Xu, P., Cao, X., Wu, C., Gu, C., He, X., Wang, X., Huang, S., Yuan, Q., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.27.474273 · Cited by 16

Antibody feedback regulation of memory B cell development in SARS-CoV-2 mRNA vaccinationPreprint

Schaefer-Babajew, D. J., Wang, Z., Muecksch, F., Cho, A., Raspe, R., Johnson, B. A., Canis, M., DaSilva, J., Ramos, V., Turroja, M., et al. (2022) · medRxiv · doi:10.1101/2022.08.05.22278483 · Cited by 16

Convergence of immune escape strategies highlights plasticity of SARS-CoV-2 spike

Yu, X., Juraszek, J., Rutten, L., Bakkers, M. J. G., Blokland, S., Melchers, J. M., van den Broek, N. J. F., Verwilligen, A., Abeywickrema, P. D., Vingerhoets, J., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011308 · Cited by 16

Structural basis for translation inhibition by MERS-CoV Nsp1 reveals a conserved mechanism for betacoronaviruses

Devarkar, S., Vetick, M. B., Balaji, S., Lomakin, I., Yang, L.-J., Jin, D., Gilbert, W. V., Chen, S.-D., & Xiong, Y. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113156 · Cited by 15

Antibody evasion associated with the RBD significant mutations in several emerging SARS-CoV-2 variants and its subvariants

Bhattacharya, M., Chatterjee, S., Lee, S., Dhama, K., & Chakraborty, C. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101008 · Cited by 16

Therapeutic antibodies and alternative formats against SARS-CoV-2

Winiger, R. R., & Perez, L. H. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105820 · Cited by 16

SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients?

Ameratunga, R., Leung, E. Y., Woon, S., Chan, L., Steele, R. H., Lehnert, K., & Longhurst, H. J. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.06.011 · Cited by 15

Landscape-Based Protein Stability Analysis and Network Modeling of Multiple Conformational States of the SARS-CoV-2 Spike D614G Mutant: Conformational Plasticity and Frustration-Induced Allostery as Energetic Drivers of Highly Transmissible Spike Variants

Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00124 · Cited by 16

Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants

Changrob, S., Halfmann, P., Liu, H., Torres, J. L., McGrath, J. J. C., Ozorowski, G., Li, L., Wilbanks, G. D., Kuroda, M., Maemura, T., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166844 · Cited by 13

IFN-λ uniquely promotes CD8 T cell immunity against SARS-CoV-2 relative to type I IFN

Solstad, A., Denz, P. J., Kenney, A. D., Mahfooz, N. S., Speaks, S., Gong, Q., Robinson, R., Long, M. E., Forero, A., Yount, J. S., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.171830 · Cited by 13

Antibodies utilizing VL6-57 light chains target a convergent cryptic epitope on SARS-CoV-2 spike protein and potentially drive the genesis of Omicron variants

Yan, Q., Gao, X., Liu, B., Hou, R., He, P., Ma, Y., Zhang, Y., Zhang, Y., Li, Z., Chen, Q., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51770-3 · Cited by 15

ScanNet: A Web Server for Structure-based Prediction of Protein Binding Sites with Geometric Deep Learning

Tubiana, J., Schneidman‐Duhovny, D., & Wolfson, H. J. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167758 · Cited by 15

Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways

Zhao, F., Keating, C., Ozorowski, G., Shaabani, N., Francino-Urdaniz, I. M., Barman, S., Limbo, O., Burns, A., Zhou, P.-P., Ricciardi, M. J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104914 · Cited by 14

SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usagePreprint

Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Chen, P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.09.434497 · Cited by 14

Structural and functional characterizations of altered infectivity and immune evasion of SARS-CoV-2 Omicron variantPreprint

Cui, Z., Liu, P., Wang, N., Wang, L., Fan, K., Zhu, Q., Wang, K., Chen, R., Feng, R., Jia, Z., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.29.474402 · Cited by 14

David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors

Alfaleh, M. A., Zawawi, A., Alamri, S. S., & Hashem, A. M. (2022) · mAbs · doi:10.1080/19420862.2022.2057832 · Cited by 13

SARS-related coronavirus S-protein structures reveal synergistic RBM interactions underpinning high-affinity human ACE2 binding

Wang, J., Ma, Y., Li, Z., Yuan, H., Liu, B., Li, Z., Su, M., Habib, G., Liu, Y., Fu, L., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr8772 · Cited by 14

Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody

Yue, S., Li, Z., Lin, Y., Yang, Y., Yuan, M., Pan, Z., Li, H., Gao, L., Zhou, J., Tang, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.751584 · Cited by 13

Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology

Ochola, L. B., Ogongo, P., Mbugua, S. M., Gitaka, J., & Suliman, S. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.10.005 · Cited by 13

SARS‐CoV‐2 evolves to reduce but not abolish neutralizing action

Zhang, Y., Ndzouboukou, J. B., Lin, X., Hou, H., Wang, F., Yuan, L., Gan, M., Yao, Z., Fu, H., Cao, J., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28207 · Cited by 12

When Do We Need Massive Computations to Perform Detailed COVID‐19 Simulations?

Lutz, C. B., & Giabbanelli, P. J. (2021) · Advanced Theory and Simulations · doi:10.1002/adts.202100343 · Cited by 13

Molecular basis of SARS-CoV-2 Omicron variant receptor engagement and antibody evasion and neutralizationPreprint

Qin, H., Han, W., Li, J., Xu, S., Wang, Y., Li, Z., Wang, Y., Zhang, C., Huang, Z. W., & Cong, Y. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.10.475532 · Cited by 13

Omicron BA.2 specifically evades broad sarbecovirus neutralizing antibodiesPreprint

Cao, Y., Yisimayi, A., Jian, F., Xiao, T., Song, W., Wang, J., Du, S., Zhang, Z., Liu, P., Hao, X., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.07.479349 · Cited by 10

Global Prevalence of Adaptive and Prolonged Infections’ Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein

Lennerstrand, J., & Palanisamy, N. (2021) · Viruses · doi:10.3390/v13101974 · Cited by 12

Biophysical Fitness Landscape of the SARS-CoV-2 Delta Variant Receptor Binding Domain

Patrick, C., Upadhyay, V., Lucas, A., & Mallela, K. M. G. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167622 · Cited by 12

The Key Site Variation and Immune Challenges in SARS-CoV-2 Evolution

Liu, Y., & Ye, Q. (2023) · Vaccines · doi:10.3390/vaccines11091472 · Cited by 12

Immunological drivers of zoonotic virus emergence, evolution, and endemicity

Purushotham, J. N., Lutz, H. L., Parker, E., & Andersen, K. G. (2025) · Immunity · doi:10.1016/j.immuni.2025.03.014 · Cited by 15

Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants

Qu, Y., Zhang, X., Wang, M., Sun, L., Jiang, Y., Li, C., Wu, W., Chen, Z., Yin, Q., Jiang, X., et al. (2021) · Virologica Sinica · doi:10.1007/s12250-021-00409-4 · Cited by 14

Additional mutations based on Omicron BA.2.75 mediate its further evasion from broadly neutralizing antibodies

Guo, H., Jiang, J., Shen, S., Ge, X., Fan, Q., Zhou, B., Cheng, L., Ju, B., & Zhang, Z. (2023) · iScience · doi:10.1016/j.isci.2023.106283 · Cited by 12

Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2

Chiang, H.-L., Liang, K.-H., Lu, R., Kuo, T.-W., Lin, Y., & Wu, H. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00955-x · Cited by 12

Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual

Guerra, D., Beaumont, T., Radić, L., Kerster, G., van der Straten, K., Yuan, M., Torres, J. L., Lee, W.-H., Liu, H., Poniman, M., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108009 · Cited by 13

Insights into SARS-CoV-2’s Mutations for Evading Human Antibodies: Sacrifice and Survival

Luan, B., & Huynh, T. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00311 · Cited by 59

Exploring the immune evasion of SARS-CoV-2 variant harboring E484K by molecular dynamics simulations

Wu, L., Peng, C., Yang, Y., Shi, Y., Zhou, L., Xu, Z., & Zhu, W. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab383 · Cited by 26

In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion

Augusto, G. S., Mohsen, M. O., Zinkhan, S., Liu, X., Vogel, M., & Bachmann, M. F. (2021) · Allergy · doi:10.1111/all.15065 · Cited by 83

Variants of SARS-CoV-2, their effects on infection, transmission and neutralization by vaccine-induced antibodies.

Wahid, M., Jawed, A., Mandal, R. K., Dailah, H. G., Janahi, E. M. A., Dhama, K., Somvanshi, P., & Haque, S. (2021) · PubMed · doi:10.26355/eurrev_202109_26805 · Cited by 28

Structure-based analyses of neutralization antibodies interacting with naturally occurring SARS-CoV-2 RBD variants

Xu, H., Wang, B., Zhao, T.-N., Liang, Z., Peng, T., Song, X., Wu, J., Wang, Y., & Su, X. (2021) · Cell Research · doi:10.1038/s41422-021-00554-1 · Cited by 13